CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ('HBM' or the 'Company'; ...
In this free webinar, learn about advancements in cell line development and glycoengineering. Attendees will gain insights into how precise glycan modulation boosts antibody-dependent cell-mediated ...
MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi ® ...
Nadunolimab's additional potential in mitigating neuropathy demonstrated by data from Cantargia's CESTAFOUR and CAPAFOUR clinical studiesPotential neuroprotective effect ...
Q4 2024 Earnings Call Transcript March 27, 2025 Innate Pharma S.A. misses on earnings expectations. Reported EPS is $-0.33474 ...
About nadunolimab (CAN04) The antibody nadunolimab binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1a and IL-1ß signaling. Nadunolimab can thereby counteract ...
Monoclonal antibody (mAb)-based immunotherapy is an ... mAb therapy involves a range of mechanisms, including ADCC, complement-dependent cytotoxicity and interference with receptor–ligand ...
Sun Pharmaceutical Industries has agreed to acquire Checkpoint Therapeutics, Inc. for $4.10 per share, a 65% premium to last traded price, post-FDA approval of Unloxcyt for metastatic cutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback